Independent regulation of renin–angiotensin–aldosterone system in the kidney

Clinical and Experimental Nephrology

Volumn 22, Issue 6, 2018, Pages 1231-1239

  Nishiyama, Akira ^a   Kobori, Hiroyuki ^b  

^a KAGAWA UNIVERSITY   (Japan)

^b INTERNATIONAL UNIVERSITY OF HEALTH AND WELFARE   (Japan)

Author keywords

Angiotensin II (Ang II); Angiotensinogen; Kidney; Renin angiotensin aldosterone system (RAAS)

Indexed keywords

ALDOSTERONE; ANGIOTENSIN II; ANGIOTENSINOGEN; MINERALOCORTICOID RECEPTOR; RENIN;

FIBROBLAST; HUMAN; HYPERTENSION; INTERSTITIAL FLUID; KIDNEY; KIDNEY BLOOD FLOW; KIDNEY INJURY; MESANGIUM CELL; PATHOGENESIS; PODOCYTE; PROTEIN FUNCTION; REGULATORY MECHANISM; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; BIOSYNTHESIS; BLOOD; ENZYME LINKED IMMUNOSORBENT ASSAY; KIDNEY DISEASE; PHYSIOLOGY; URINE;

ANGIOTENSIN II; ANGIOTENSINOGEN; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; HYPERTENSION; KIDNEY; KIDNEY DISEASES; RENIN; RENIN-ANGIOTENSIN SYSTEM;

EID: 85044512641     PISSN: 13421751     EISSN: 14377799     Source Type: Journal    
DOI: 10.1007/s10157-018-1567-1     Document Type: Review

References (95)

1. Nishiyama A, Kim-Mitsuyama S. New approaches to blockade of the renin-angiotensin-aldosterone system: Overview of regulation of the renin-angiotensin-aldosterone system. J Pharmacol Sci. 2010;113(Issue):289–91
2. Navar LG, Inscho EW, Majid SA, Imig JD, Harrison-Bernard LM, Mitchell KD. Paracrine regulation of the renal microcirculation. Physiol Rev. 1996;76(Issue):425–536. 10.1152/physrev.1996.76.2.425
3. Nishiyama A, Hitomi H, Rahman A, Kiyomoto H. Drug discovery for overcoming chronic kidney disease (ckd): Pharmacological effects of mineralocorticoid-receptor blockers. J Pharmacol Sci. 2009;109(Issue):1–6
4. Kobori H, Nangaku M, Navar LG, Nishiyama A. The intrarenal renin-angiotensin system: From physiology to the pathobiology of hypertension and kidney disease. Pharmacol Rev. 2007;59(Issue):251–87. 10.1124/pr.59.3.3
5. Kobori H, Ozawa Y, Suzaki Y, Prieto-Carrasquero MC, Nishiyama A, Shoji T, et al. Young scholars award lecture: Intratubular angiotensinogen in hypertension and kidney diseases. Am J Hypertens. 2006;19(Issue):541–50. 10.1016/j.amjhyper.2005.11.014
6. Nagai Y, Yao L, Kobori H, Miyata K, Ozawa Y, Miyatake A, et al. Temporary angiotensin II blockade at the prediabetic stage attenuates the development of renal injury in type 2 diabetic rats. J Am Soc Nephrol. 2005;16(Issue):703–11. 10.1681/ASN.2004080649
7. Navar LG, Nishiyama A. Intrarenal formation of angiotensin II. Contrib Nephrol. 2001;(135):1–15
8. Nishiyama A, Kobori H, Fukui T, Zhang GX, Yao L, Rahman M, et al. Role of angiotensin II and reactive oxygen species in cyclosporine a-dependent hypertension. Hypertension. 2003;42(Issue):754–60. 10.1161/01.HYP.0000085195.38870.44
9. Nishiyama A, Konishi Y, Ohashi N, Morikawa T, Urushihara M, Maeda I, et al. Urinary angiotensinogen reflects the activity of intrarenal renin-angiotensin system in patients with iga nephropathy. Nephrol Dial Transpl. 2011;26(Issue):170–7. 10.1093/ndt/gfq371
10. Kobori H, Mori H, Masaki T, Nishiyama A. Angiotensin II blockade and renal protection. Curr Pharm Des. 2013;19(Issue):3033–42
11. Fan YY, Kobori H, Nakano D, Hitomi H, Mori H, Masaki T, et al. Aberrant activation of the intrarenal renin-angiotensin system in the developing kidneys of type 2 diabetic rats. Horm Metab Res. 2013;45(Issue):338–43. 10.1055/s-0032-1331256
12. Nishiyama A, Nakagawa T, Kobori H, Nagai Y, Okada N, Konishi Y, et al. Strict angiotensin blockade prevents the augmentation of intrarenal angiotensin II and podocyte abnormalities in type 2 diabetic rats with microalbuminuria. J Hypertens. 2008;26(Issue):1849–59. 10.1097/HJH.0b013e3283060efa
13. Siragy HM, Carey RM. Protective role of the angiotensin AT2 receptor in a renal wrap hypertension model. Hypertension. 1999;33(Issue):1237–42
14. Navar LG, Mitchell KD, Harrison-Bernard LM, Kobori H, Nishiyama A. Review. Intrarenal angiotensin II levels in normal and hypertensive states. J Renin Angiotensin Aldosterone Syst. 2001;2(Issue):S176-S84. 10.1177/14703203010020013001
15. Nishiyama A, Hasegawa K, Diah S, Hitomi H. New approaches to blockade of the renin-angiotensin-aldosterone system: mineralocorticoid-receptor blockers exert antihypertensive and renoprotective effects independently of the renin-angiotensin system. J Pharmacol Sci. 2010;113(Issue):310–4
16. Rafiq K, Hitomi H, Nakano D, Nishiyama A. Pathophysiological roles of aldosterone and mineralocorticoid receptor in the kidney. J Pharmacol Sci. 2011;115(Issue):1–7
17. Brasier AR, Li J. Mechanisms for inducible control of angiotensinogen gene transcription. Hypertension. 1996;27(Issue):465–75
18. Paul M, Poyan Mehr A, Kreutz R. Physiology of local renin-angiotensin systems. Physiol Rev. 2006;86(Issue):747–803. 10.1152/physrev.00036.2005
19. Hackenthal E, Paul M, Ganten D, Taugner R. Morphology, physiology, and molecular biology of renin secretion. Physiol Rev. 1990;70(Issue):1067–116. 10.1152/physrev.1990.70.4.1067
20. Baylis C, Engels K, Hymel A, Navar LG. Plasma renin activity and metabolic clearance rate of angiotensin II in the unstressed aging rat. Mech Ageing Dev. 1997;97(Issue):163–72
21. Gould AB, Green D. Kinetics of the human renin and human substrate reaction. Cardiovasc Res. 1971;5(Issue):86–9
22. Kim HS, Krege JH, Kluckman KD, Hagaman JR, Hodgin JB, Best CF, et al. Genetic control of blood pressure and the angiotensinogen locus. Proc Natl Acad Sci USA. 1995;92(Issue):2735–9
23. Kobori H, Ozawa Y, Satou R, Katsurada A, Miyata K, Ohashi N, et al. Kidney-specific enhancement of ang II stimulates endogenous intrarenal angiotensinogen in gene-targeted mice. Am J Physiol Renal Physiol. 2007;293(Issue):F938–45. 10.1152/ajprenal.00146.2007
24. Deschepper CF. Angiotensinogen. Hormonal regulation and relative importance in the generation of angiotensin II. Kidney Int. 1994;46(Issue):1561–3
25. Ichihara A, Kobori H, Nishiyama A, Navar LG. Renal renin-angiotensin system. Contrib Nephrol. 2004;143(Issue):117–30
26. Devarajan S, Yahiro E, Uehara Y, Habe S, Nishiyama A, Miura S, et al. Depressor effect of chymase inhibitor in mice with high salt-induced moderate hypertension. Am J Physiol Heart Circ Physiol. 2015;309(Issue):H1987–96. 10.1152/ajpheart.00721.2014
27. Erdos EG. Angiotensin i converting enzyme and the changes in our concepts through the years. Lewis k. Dahl memorial lecture. Hypertension. 1990;16(Issue):363–70
28. Johnston CI. Tissue angiotensin converting enzyme in cardiac and vascular hypertrophy, repair, and remodeling. Hypertension. 1994;23(Issue):258–68
29. Ingert C, Grima M, Coquard C, Barthelmebs M, Imbs JL. Contribution of angiotensin II internalization to intrarenal angiotensin II levels in rats. Am J Physiol Renal Physiol. 2002;283(Issue):F1003–10. 10.1152/ajprenal.00322.2001
30. Kobori H, Nishiyama A, Harrison-Bernard LM, Navar LG. Urinary angiotensinogen as an indicator of intrarenal angiotensin status in hypertension. Hypertension. 2003;41(Issue):42–9
31. Campbell DJ, Lawrence AC, Towrie A, Kladis A, Valentijn AJ. Differential regulation of angiotensin peptide levels in plasma and kidney of the rat. Hypertension. 1991;18(Issue):763–73
32. Komlosi P, Fuson AL, Fintha A, Peti-Peterdi J, Rosivall L, Warnock DG, et al. Angiotensin I conversion to angiotensin II stimulates cortical collecting duct sodium transport. Hypertension. 2003;42(Issue):195–9. 10.1161/01.HYP.0000081221.36703.01
33. Rosivall L, Navar LG. Effects on renal hemodynamics of intra-arterial infusions of angiotensins I and II. Am J Physiol. 1983;245(Issue):F181–7. 10.1152/ajprenal.1983.245.2.F181
34. Casarini DE, Boim MA, Stella RC, Krieger-Azzolini MH, Krieger JE, Schor N. Angiotensin i-converting enzyme activity in tubular fluid along the rat nephron. Am J Physiol. 1997;272(Issue):F405–9. 10.1152/ajprenal.1997.272.3.F405
35. Nishiyama A, Seth DM, Navar LG. Renal interstitial fluid concentrations of angiotensins I and II in anesthetized rats. Hypertension. 2002;39(Issue):129–34
36. Nishiyama A, Seth DM, Navar LG. Renal interstitial fluid angiotensin I and angiotensin II concentrations during local angiotensin-converting enzyme inhibition. J Am Soc Nephrol. 2002;13(Issue):2207–12
37. Braam B, Mitchell KD, Fox J, Navar LG. Proximal tubular secretion of angiotensin II in rats. Am J Physiol. 1993;264(Issue):F891–8. 10.1152/ajprenal.1993.264.5.F891
38. Seikaly MG, Arant BS Jr, Seney FD Jr. Endogenous angiotensin concentrations in specific intrarenal fluid compartments of the rat. J Clin Invest. 1990;86(Issue):1352–7. 10.1172/JCI114846
39. Hiranyachattada S, Harris PJ. Modulation by locally produced luminal angiotensin II of proximal tubular sodium reabsorption via an AT1 receptor. Br J Pharmacol. 1996;119(Issue):617–8
40. Quan A, Baum M. Endogenous production of angiotensin II modulates rat proximal tubule transport. J Clin Invest. 1996;97(Issue):2878–82. 10.1172/JCI118745
41. Gonzalez-Villalobos RA, Seth DM, Satou R, Horton H, Ohashi N, Miyata K, et al. Intrarenal angiotensin II and angiotensinogen augmentation in chronic angiotensin ii-infused mice. Am J Physiol Renal Physiol. 2008;295(Issue):F772–9. 10.1152/ajprenal.00019.2008
42. Li XC, Carretero OA, Navar LG, Zhuo JL. AT1 receptor-mediated accumulation of extracellular angiotensin II in proximal tubule cells: role of cytoskeleton microtubules and tyrosine phosphatases. Am J Physiol Renal Physiol. 2006;291(Issue):F375–83. 10.1152/ajprenal.00405.2005
43. Darby IA, Sernia C. In situ hybridization and immunohistochemistry of renal angiotensinogen in neonatal and adult rat kidneys. Cell Tissue Res. 1995;281(Issue):197–206
44. Kamiyama M, Garner MK, Farragut KM, Sofue T, Hara T, Morikawa T, et al. Detailed localization of augmented angiotensinogen mrna and protein in proximal tubule segments of diabetic kidneys in rats and humans. Int J Biol Sci. 2014;10(Issue):530–42. 10.7150/ijbs.8450
45. Lantelme P, Rohrwasser A, Gociman B, Hillas E, Cheng T, Petty G, et al. Effects of dietary sodium and genetic background on angiotensinogen and renin in mouse. Hypertension. 2002;39(Issue):1007–14
46. Kobori H, Harrison-Bernard LM, Navar LG. Enhancement of angiotensinogen expression in angiotensin II-dependent hypertension. Hypertension. 2001;37(Issue):1329–35
47. Kobori H, Harrison-Bernard LM, Navar LG. Expression of angiotensinogen mrna and protein in angiotensin II-dependent hypertension. J Am Soc Nephrol. 2001;12(Issue):431–9
48. Wang J, Shibayama Y, Kobori H, Liu Y, Kobara H, Masaki T, et al. High glucose augments angiotensinogen in human renal proximal tubular cells through hepatocyte nuclear factor-5. PLoS One. 2017;12(Issue):e0185600. 10.1371/journal.pone.0185600
49. Zhang SL, Filep JG, Hohman TC, Tang SS, Ingelfinger JR, Chan JS. Molecular mechanisms of glucose action on angiotensinogen gene expression in rat proximal tubular cells. Kidney Int. 1999;55(Issue):454–64. 10.1046/j.1523-1755.1999.00271.x
50. Miyata K, Ohashi N, Suzaki Y, Katsurada A, Kobori H. Sequential activation of the reactive oxygen species/angiotensinogen/renin-angiotensin system axis in renal injury of type 2 diabetic rats. Clin Exp Pharmacol Physiol. 2008;35(Issue):922–7. 10.1111/j.1440-1681.2008.04938.x
51. Kamiyama M, Urushihara M, Morikawa T, Konishi Y, Imanishi M, Nishiyama A, et al. Oxidative stress/angiotensinogen/renin-angiotensin system axis in patients with diabetic nephropathy. Int J Mol Sci. 2013;14(Issue):23045–62. 10.3390/ijms141123045
52. Ogawa S, Matsushima M, Mori T, Okamura M, Senda M, Sakamoto T, et al. Identification of the stages of diabetic nephropathy at which angiotensin II receptor blockers most effectively suppress albuminuria. Am J Hypertens. 2013;26(Issue):1064–9. 10.1093/ajh/hpt085
53. Sato E, Mori T, Satoh M, Fujiwara M, Nakamichi Y, Oba I, et al. Urinary angiotensinogen excretion is associated with blood pressure in obese young adults. Clin Exp Hypertens. 2016;38(Issue):203–8. 10.3109/10641963.2015.1081219
54. Ihara G, Kiyomoto H, Kobori H, Nagai Y, Ohashi N, Hitomi H, et al. Regression of superficial glomerular podocyte injury in type 2 diabetic rats with overt albuminuria: effect of angiotensin II blockade. J Hypertens. 2010;28(Issue):2289–98. 10.1097/HJH.0b013e32833dfcda
55. Konishi Y, Nishiyama A, Morikawa T, Kitabayashi C, Shibata M, Hamada M, et al. Relationship between urinary angiotensinogen and salt sensitivity of blood pressure in patients with iga nephropathy. Hypertension. 2011;58(Issue):205–11. 10.1161/HYPERTENSIONAHA.110.166843
56. Eriguchi M, Yotsueda R, Torisu K, Kawai Y, Hasegawa S, Tanaka S, et al. Assessment of urinary angiotensinogen as a marker of podocyte injury in proteinuric nephropathies. Am J Physiol Renal Physiol. 2016;310(Issue):F322–33. 10.1152/ajprenal.00260.2015
57. Ohashi N, Urushihara M, Satou R, Kobori H. Glomerular angiotensinogen is induced in mesangial cells in diabetic rats via reactive oxygen species–erk/jnk pathways. Hypertens Res. 2010;33(Issue):1174–81. 10.1038/hr.2010.143
58. Takamatsu M, Urushihara M, Kondo S, Shimizu M, Morioka T, Oite T, et al. Glomerular angiotensinogen protein is enhanced in pediatric iga nephropathy. Pediatr Nephrol. 2008;23(Issue):1257–67. 10.1007/s00467-008-0801-6
59. Zhang SL, Tang SS, Chen X, Filep JG, Ingelfinger JR, Chan JS. High levels of glucose stimulate angiotensinogen gene expression via the p38 mitogen-activated protein kinase pathway in rat kidney proximal tubular cells. Endocrinology. 2000;141(Issue):4637–46. 10.1210/endo.141.12.7844
60. Hsieh TJ, Zhang SL, Filep JG, Tang SS, Ingelfinger JR, Chan JS. High glucose stimulates angiotensinogen gene expression via reactive oxygen species generation in rat kidney proximal tubular cells. Endocrinology. 2002;143(Issue):2975–85. 10.1210/endo.143.8.8931
61. Kobori H, Nishiyama A. Effects of tempol on renal angiotensinogen production in dahl salt-sensitive rats. Biochem Biophys Res Commun. 2004;315(Issue):746–50. 10.1016/j.bbrc.2004.01.120
62. Li J, Brasier AR. Angiotensinogen gene activation by angiotensin II is mediated by the rel a (nuclear factor-kappab p65) transcription factor: one mechanism for the renin angiotensin system positive feedback loop in hepatocytes. Mol Endocrinol. 1996;10(Issue):252–64. 10.1210/mend.10.3.8833654
63. Brinkmann MM, Glenn M, Rainbow L, Kieser A, Henke-Gendo C, Schulz TF. Activation of mitogen-activated protein kinase and nf-kappab pathways by a kaposi’s sarcoma-associated herpesvirus k15 membrane protein. J Virol. 2003;77(Issue):9346–58
64. Hoffmann E, Thiefes A, Buhrow D, Dittrich-Breiholz O, Schneider H, Resch K, et al. Mek1-dependent delayed expression of fos-related antigen-1 counteracts c-fos and p65 nf-kappab-mediated interleukin-8 transcription in response to cytokines or growth factors. J Biol Chem. 2005;280(Issue):9706–18. 10.1074/jbc.M407071200
65. Ding Y, Davisson RL, Hardy DO, Zhu LJ, Merrill DC, Catterall JF, et al. The kidney androgen-regulated protein promoter confers renal proximal tubule cell-specific and highly androgen-responsive expression on the human angiotensinogen gene in transgenic mice. J Biol Chem. 1997;272(Issue):28142–8
66. Nakano D, Kobori H, Burford JL, Gevorgyan H, Seidel S, Hitomi H, et al. Multiphoton imaging of the glomerular permeability of angiotensinogen. J Am Soc Nephrol. 2012;23(Issue):1847–56. 10.1681/ASN.2012010078
67. Roksnoer LC, Verdonk K, van den Meiracker AH, Hoorn EJ, Zietse R, Danser AH. Urinary markers of intrarenal renin-angiotensin system activity in vivo. Curr Hypertens Rep. 2013;15(Issue):81–8. 10.1007/s11906-012-0326-z
68. Zhuang Z, Bai Q, Lata A, Liang Y, Zheng D, Wang Y. Changes of urinary angiotensinogen concentration and its association with urinary proteins in diabetic rats. Int J Clin Exp Pathol. 2015;8(Issue):11946–56
69. Saito T, Urushihara M, Kotani Y, Kagami S, Kobori H. Increased urinary angiotensinogen is precedent to increased urinary albumin in patients with type 1 diabetes. Am J Med Sci. 2009;338(Issue):478–80. 10.1097/MAJ.0b013e3181b90c25
70. Zhuang Z, Bai Q, Liang AL, Zheng Y, Wang D. Y. Increased urinary angiotensinogen precedes the onset of albuminuria in normotensive type 2 diabetic patients. Int J Clin Exp Pathol. 2015;8(Issue):11464–9
71. Soltysiak J, Skowronska B, Fichna P, Ostalska-Nowicka D, Stankiewicz W, Lewandowska-Stachowiak M, et al. Urinary angiotensinogen and urinary sodium are associated with blood pressure in normoalbuminuric children with diabetes. Pediatr Nephrol. 2014;29(Issue):2373–8. 10.1007/s00467-014-2861-0
72. Kobori H, Alper AB Jr, Shenava R, Katsurada A, Saito T, Ohashi N, et al. Urinary angiotensinogen as a novel biomarker of the intrarenal renin-angiotensin system status in hypertensive patients. Hypertension. 2009;53(Issue):344–50. 10.1161/HYPERTENSIONAHA.108.123802
73. Kobori H, Ohashi N, Katsurada A, Miyata K, Satou R, Saito T, et al. Urinary angiotensinogen as a potential biomarker of severity of chronic kidney diseases. J Am Soc Hyperten. 2008;2(Issue):349–54. 10.1016/j.jash.2008.04.008
74. van den Heuvel M, Batenburg WW, Jainandunsing S, Garrelds IM, van Gool JM, Feelders RA, et al. Urinary renin, but not angiotensinogen or aldosterone, reflects the renal renin-angiotensin-aldosterone system activity and the efficacy of renin-angiotensin-aldosterone system blockade in the kidney. J Hypertens. 2011;29(Issue):2147–55. 10.1097/HJH.0b013e32834bbcbf
75. Matsusaka T, Niimura F, Pastan I, Shintani A, Nishiyama A, Ichikawa I. Podocyte injury enhances filtration of liver-derived angiotensinogen and renal angiotensin II generation. Kidney Int. 2014;85(Issue):1068–77. 10.1038/ki.2013.453
76. Matsusaka T, Niimura F, Shimizu A, Pastan I, Saito A, Kobori H, et al. Liver angiotensinogen is the primary source of renal angiotensin II. J Am Soc Nephrol. 2012;23(Issue):1181–9. 10.1681/ASN.2011121159
77. Kobori H, Harrison-Bernard LM, Navar LG. Urinary excretion of angiotensinogen reflects intrarenal angiotensinogen production. Kidney In. 2002;61(Issue):579–85. 10.1046/j.1523-1755.2002.00155.x
78. Katsurada A, Hagiwara Y, Miyashita K, Satou R, Miyata K, Ohashi N, et al. Novel sandwich elisa for human angiotensinogen. Am J Physiol Renal Physiol. 2007;293(Issue):F956–60. 10.1152/ajprenal.00090.2007
79. Nishijima Y, Kobori H, Sofue T, Kaifu K, Moriwaki K, Hara T, et al. Important aspects of urine sampling for angiotensinogen measurement: time and preservation conditions in healthy individuals. Tohoku J Exp Med. 2012;228(Issue):333–9
80. Nishijima Y, Kobori H, Kaifu K, Mizushige T, Hara T, Nishiyama A, et al. Circadian rhythm of plasma and urinary angiotensinogen in healthy volunteers and in patients with chronic kidney disease. J Renin Angiotensin Aldosterone Syst. 2014;15(Issue):505–8. 10.1177/1470320314557584
81. Kobori H, Urushihara M, Xu JH, Berenson GS, Navar LG. Urinary angiotensinogen is correlated with blood pressure in men (bogalusa heart study). J Hypertens. 2010;28(Issue):1422–8. 10.1097/HJH.0b013e3283392673
82. Mills KT, Kobori H, Hamm LL, Alper AB, Khan IE, Rahman M, et al. Increased urinary excretion of angiotensinogen is associated with risk of chronic kidney disease. Nephrol Dial Transpl. 2012;27(Issue):3176–81. 10.1093/ndt/gfs011
83. Mizushige T, Kobori H, Nishijima Y, Yano Y, Sakata K, Hayakawa M, et al. Urinary angiotensinogen could be a prognostic marker of renoprotective effects of alogliptin in patients with type 2 diabetes. J Diabetes Res. 2015;2015(Issue):517472. 10.1155/2015/517472
84. Sawaguchi M, Araki SI, Kobori H, Urushihara M, Haneda M, Koya D, et al. Association between urinary angiotensinogen levels and renal and cardiovascular prognoses in patients with type 2 diabetes mellitus. J Diabetes Investig. 2012;3(Issue):318–24
85. Kobori H, Nishiyama A, Abe Y, Navar LG. Enhancement of intrarenal angiotensinogen in dahl salt-sensitive rats on high salt diet. Hypertension. 2003;41(Issue):592–7. 10.1161/01.HYP.0000056768.03657.B4
86. Zou J, Li Y, Li FH, Wei FF, Wang JG. Urinary angiotensinogen excretion and ambulatory blood pressure. J Hypertens. 2012;30(Issue):2000–6. 10.1097/HJH.0b013e3283576928
87. Tiryaki O, Usalan C. Association between urinary angiotensinogen excretion rates and left ventricular mass index and carotid intima-media thickness in hypertensive kidney transplant recipients. Clin Transpl. 2015;29(Issue):351–8. 10.1111/ctr.12521
88. Rafiq K, Noma T, Fujisawa Y, Ishihara Y, Arai Y, Nabi AH, et al. Renal sympathetic denervation suppresses de novo podocyte injury and albuminuria in rats with aortic regurgitation. Circulation. 2012;125(Issue):1402–13. 10.1161/CIRCULATIONAHA.111.064097
89. Satirapoj B, Siritaweesuk N, Supasyndh O. Urinary angiotensinogen as a potential biomarker of diabetic nephropathy. Clin Kidney J. 2014;7(Issue):354–60. 10.1093/ckj/sfu059
90. Kurultak I, Sengul S, Kocak S, Erdogmus S, Calayoglu R, Mescigil P, et al. Urinary angiotensinogen, related factors and clinical implications in normotensive autosomal dominant polycystic kidney disease patients. Ren Fail. 2014;36(Issue):717–21. 10.3109/0886022X.2014.890857
91. Park HC, Kang AY, Jang JY, Kim H, Han M, Oh KH, et al. Increased urinary angiotensinogen/creatinine (agt/cr) ratio may be associated with reduced renal function in autosomal dominant polycystic kidney disease patients. BMC Nephrol. 2015;16(Issue):86. 10.1186/s12882-015-0075-8
92. Alge JL, Karakala N, Neely BA, Janech MG, Tumlin JA, Chawla LS, et al. Urinary angiotensinogen and risk of severe aki. Clin J Am Soc Nephrol. 2013;8(Issue):184–93. 10.2215/CJN.06280612
93. Alge JL, Karakala N, Neely BA, Janech MG, Velez JC, Arthur JM, et al. Urinary angiotensinogen predicts adverse outcomes among acute kidney injury patients in the intensive care unit. Crit Care. 2013;17(Issue):R69. 10.1186/cc12612
94. Kitao T, Kimata T, Yamanouchi S, Kato S, Tsuji S, Kaneko K. Urinary biomarkers for screening for renal scarring in children with febrile urinary tract infection: Pilot study. J Urol. 2015;194(Issue):766–71. 10.1016/j.juro.2015.04.091
95. Corvol P, Lamande N, Cruz A, Celerier J, Gasc JM. Inhibition of angiogenesis: a new function for angiotensinogen and des(angiotensin I)angiotensinogen. J Urol. 2003;5(Issue):149–54